Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$12.03
+0.18 (+1.52%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $4.4M · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.0B
P/E
14.9x
↓EV/EBITDA
9.1x
↓ROE
17.8%
↑Gross Margin
72.9%
↑Debt/Equity
0.20
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+10.2%
FCF CAGR
—
FCF margin
-0.2%
FCF / Net income
-0.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.11B · net income $472.8M · FCF $-5.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.11B | $3.11B | $2.93B | $2.69B | $2.33B |
| Net Income | $472.8M | $472.8M | $512.4M | $368.3M | $269.7M |
| EBITDA | $665.7M | $665.7M | $685.8M | $484.7M | $368.3M |
| EPS | 0.95 | 0.95 | 1.04 | 0.73 | 0.59 |
| Gross Margin | 72.9% | 72.9% | 73.2% | 77.2% | 77.8% |
| Operating Margin | 18.7% | 18.7% | 20.1% | 15.3% | 13.8% |
| Net Margin | 15.2% | 15.2% | 17.5% | 13.7% | 11.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.20 | 0.20 | 0.12 | 0.20 | 0.20 |
| Current Ratio | 3.73 | 3.73 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-5.8M | $-5.8M | $348.5M | $4.4M | $-144.4M |
| Returns | |||||
| ROE | 17.8% | 17.8% | 20.3% | 18.7% | 17.4% |
| Valuation | |||||
| P/E | 14.85 | 14.85 | 16.32 | 31.41 | 28.78 |
| EV/EBITDA | 9.11 | 9.11 | 11.99 | 23.79 | 20.99 |
| P/B | 2.25 | 2.25 | 3.31 | 5.86 | 5.00 |
| Growth & Yield | |||||
| Revenue Growth | 6.1% | 6.1% | 8.8% | 15.7% | — |
| EPS Growth | -8.7% | -8.7% | 42.5% | 24.6% | — |
| Dividend Yield | 3.4% | 3.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
4.0%
EPS terminal req.
$1.07
Spread vs growth
-12.6%
5Y implied EPS CAGR
6.3%
EPS terminal req.
$1.29
Spread vs growth
-15.0%
10Y implied EPS CAGR
8.2%
EPS terminal req.
$2.08
Spread vs growth
-16.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-21.8%
Start / end P/E
15.5x → 12.7x
EPS bridge
1.04 → 0.95
Residual
+1.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.